Diabetes is an important cardiovascular risk factor, but until recently a disconnect has existed between management of type 2 diabetes and reduction of cardiovascular mortality and morbidity. Such was the mixed impact of previous generations of antihyperglycaemic drugs that the US and European drug regulators mandated cardiovascular outcome studies to assess the safety of all future therapeutic interventions. Somewhat ironically, this move unveiled an unexpected but welcome cardiovascular benefit with some newer generation drugs, including the sodium-glucose co-transporter-2 (SGLT2) inhibitors.

中文翻译：

---

SGLT2抑制剂：关于心血管保护机制的假设

糖尿病是重要的心血管危险因素，但直到最近，在控制2型糖尿病与降低心血管疾病死亡率和发病率之间仍存在脱节。这是前几代降血糖药的混合影响，美国和欧洲的药物监管机构要求进行心血管结局研究，以评估所有未来治疗性干预措施的安全性。颇具讽刺意味的是，此举带来了一些新型药物（包括钠-葡萄糖共转运蛋白2（SGLT2）抑制剂）带来意想不到但令人欢迎的心血管益处。